Q-omics provides the consensus-scored FAM177A1P1 profile across patient tissues and cancer cell-line models. FAM177A1P1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM177A1P1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, FAM177A1P1 RNA expression shows 6,507 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where FAM177A1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM177A1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM177A1P1 survival associations across molecular data types. FAM177A1P1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM177A1P1 RNA expression–survival associations across cancer types. High FAM177A1P1 expression shows unfavorable associations in HNSC, LUSC, MESO, KIRC and PAAD, but favorable associations in PRAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM177A1P1 RNA expression.
This table summarizes FAM177A1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM177A1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM177A1P1 shows lower tumor expression in THCA, COAD and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher FAM177A1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .026).
This table shows molecular features associated with FAM177A1P1 in patient tissues and cancer cell lines. In patient samples, FAM177A1P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
